ENGN Dividende : enGene Therapeutics Inc Analyse du rendement



Dividendes

ENGN Dividendes

enGene Therapeutics Inc

$1.72

-80.56%

$-7.13

À la fermeture : May 07, 16:00:00 GMT-4

$1.72

0.02%

$0

Post-Marché: May 07, 20:37:24 GMT-4

Aperçu Prévision Gagner Dividendes Comptes financiers

Statistiques clés

Clôture préc.

$8.85

Prix d'ouverture

$2.14

Plage de la journée

$1.7 - $2.24

Plage de 52 semaines

$1.72 - $12.25

Volume

23.4M

Volume moyen

401.2K

Rendement en dividend

BPA (TTM)

-2.25

Capitalisation boursière

$115.2M

Qu’est-ce que ENGN ?

enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).